ClinicalTrials.gg
RecruitingNCT05848310Updated Mar 27, 2026

Preoperative Serum FGF19 in the Prognosis of Biliary Atresia

An observational study in Biliary Atresia and Prognosis, sponsored by Children's Hospital of Fudan University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Children's Hospital of Fudan University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
200
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Biliary Atresia with a site in China — 7 open to participants now, 9 under way, 1 of them phase 3. Biliary Atresia · China.

Planned enrollment
5th of 10
200 · median 200
Started
2023
with 3 others
Observational
10 of 21
5 open now
Registered
14th of 21
by date
Lead sponsor
4 of 21
Children's Hospital of Fudan University

Among the 21 studies in Biliary Atresia with a site in China, this one is the 5th largest by planned enrollment of the 10 observational ones that give a count, is one of 4 that started in 2023, is one of 10 observational ones, and was the 14th registered.

Biliary Atresia

78 studies on the registry are indexed under Biliary Atresia; 26 are open to participants now.

Browse Biliary Atresia studies →

Open to participants now

7 of the 21 studies in Biliary Atresia with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 21 Biliary Atresia studies recruiting now, 3 (14%) set no upper age limit and 18 (86%) stop at 75 or younger; 21 take children under 18; 6 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Biliary Atresia with a site in China, or all of them as a file.
02

Study summary

To investigate the role of preoperative serum FGF19 level in the prognosis of biliary atresia.

Read the detailed description

Kasai portoenterostomy is currently one of the main treatment methods for biliary atresia, but about 30% of children still require liver transplantation even after receiving the surgery. Accurate prognosis will help select the most suitable treatment method for children, but there is currently a lack of effective preoperative predictive indicators. Serum FGF19 has recently been considered a possible preoperative predictive indicator for biliary atresia, but its predictive value has not been confirmed in a large sample and in Asian population, thus the investigators try to further explore the prognostic value of serum FGF19 in children with biliary atresia based on a large sample.

03

Conditions studied

  • Biliary Atresia
  • Prognosis

Browse trials for

Keywords

  • Biliary Atresia
  • FGF19
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study enrolled patients meeting following conditions.

  • Patients diagnosed as biliary atresia in Children's Hospital of Fudan University
  • Patients with at least one-year follow-up records after surgery
  • Patients with a record of serum total bilirubin levels three months after surgery
  • Patients with preoperative serum left(volume > 500ul)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Samples diagnosed as biliary atresia in Children's Hospital of Fudan University
  • Samples with one-year follow-up records after surgery
  • Samples with a record of serum total levels three months after surgery
  • Samples with preoperative serum left(volume > 500ul)

Exclusion criteria

Exclusion Criteria:

  • None
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Good prognosis + Poor prognosis

    Good prognosis: the serum total bilirubin level was less than 20 umol/l three months after surgery, and no liver transplantation or death occurred within a year after surgery. Poor prognosis: the serum total bilirubin level was higher than 20 umol/l three months after surgery, and no liver transplantation or death occurred within a year after surgery.

06

What researchers measure

Primary outcomes

  1. Serum total bilirubin level (umol/l)

    The difference of serum total bilirubin level will be measured with ELISA( Enzyme Linked ImmunoSorbent Assay) three months after surgery

    Time frame: Three months after surgery

  2. Native liver survival (%)

    The difference of native liver survival will be measured according to the follow-up statue one year after surgery

    Time frame: One year after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for Jun 2026, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2023
First posted
May 8, 2023
StartActual
Oct 15, 2023
Primary completionEst.
Jun 2026
CompletionEst.
Aug 2027
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05848310
Responsible party
Sponsor
First posted
May 8, 2023
Start date
Oct 15, 2023
Primary completion
Jun 2026 (estimated)
Completion
Aug 2027 (estimated)
Last update
Mar 27, 2026

Study contacts

Shan Zheng
Contact
szheng@shmu.edu.cn
+86 021 64932791
Jiajie Zhu
Contact
jiajiez98@163.com
+86 021 18268899251

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion